Market Cap 580.41M
Revenue (ttm) 573.28M
Net Income (ttm) -33.54M
EPS (ttm) N/A
PE Ratio 13.42
Forward PE 14.13
Profit Margin -5.85%
Debt to Equity Ratio 1.70
Volume 248,200
Avg Vol 424,736
Day's Range N/A - N/A
Shares Out 82.68M
Stochastic %K 86%
Beta 0.81
Analysts Strong Sell
Price Target $12.75

Company Profile

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise of various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain. It also offers precision bone resection for pat...

Industry: Medical Devices
Sector: Healthcare
Phone: 919 474 6700
Address:
4721 Emperor Boulevard, Suite 100, Durham, United States
highnihilism
highnihilism Sep. 22 at 12:52 PM
IWM: Russell 2000 → $CIA Citizens $ACRS Aclaris Therapeutics $PWP Perella Weinberg Partners $APOG Apogee Enterprises $BVS Bioventus
0 · Reply
highnihilism
highnihilism Sep. 17 at 9:40 AM
IWM: Russell 2000 → $CIA Citizens $ACRS Aclaris Therapeutics $PWP Perella Weinberg Partners $APOG Apogee Enterprises $BVS Bioventus Class A
0 · Reply
theDIOyears
theDIOyears Sep. 17 at 4:26 AM
$BVS looking to get in. Anyone able to give me a quick rundown?
0 · Reply
B2iDigital
B2iDigital Sep. 8 at 9:20 PM
Xtant Medical Holdings (NYSE-American: $XTNT) announced that Sean Browne, CEO, and Scott Neils, CFO, will participate in the H.C. Wainwright 27th Annual Global Investment Conference. Xtant Medical is a B2i Digital Featured Company. View the comprehensive profile at https://b2idigital.com/xtant-medical-1. H.C. Wainwright’s 27th Annual Global Investment Conference takes place in New York and virtually, September 8-10, 2025. The company presentation will be available on demand as of Friday, September 5 at 7:00 A.M. (ET). Xtant’s management team will be available for virtual one-on-one meetings on September 8th. Interested investors should contact their representative at H.C. Wainwright & Co., LLC. To register for the event and view the company’s presentation, visit: https://journey.ct.events/view/099ddf07-0cfd-43e7-b98f-ca41f0bc9d7f See the news release at: https://investor.xtantmedical.com/news-releases/news-release-details/xtant-medical-participate-hc-wainwright-27th-annual-global Xtant Medical is led by Chief Executive Officer Sean Browne, Chief Financial Officer Scott Neils, and Chief Operating Officer Mark Schallenberger, who bring extensive expertise in medical device commercialization, corporate finance, and orthobiologic innovation. For more information, visit https://www.xtantmedical.com. Investor inquiries: Kevin Gardner at LifeSci Advisors, [email protected]. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted XTNT stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of XTNT or any security, and it is not intended to offer any opinion on XTNT as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $OFIX $BVS
1 · Reply
Eagley3k
Eagley3k Aug. 26 at 7:57 PM
0 · Reply
Eagley3k
Eagley3k Aug. 26 at 7:51 PM
$BVS big battle at 200 WMA support level @$7.10. lets see what happens. in for a pop.
0 · Reply
VectorVanguard
VectorVanguard Aug. 23 at 8:10 AM
$BVS Bioventus Inc is a medical device company facing product challenges and restructuring
0 · Reply
MrTicker
MrTicker Jul. 30 at 2:33 PM
$BVS 10:31 AM EDT, 07/30/2025 (MT Newswires) -- Bioventus(BVS) said Wednesday that the US Food and Drug Administration has given 510(k) clearances for TalisMann and StimTrial, the company's peripheral nerve stimulation, or PNS, devices for chronic pain management. TalisMann targets deeper, larger nerves and is designed to provide long-term relief from chronic nerve pain. StimTrial allows doctors to test how patients respond to PNS therapy before starting full treatment, the company said. The company added that it expects to begin a limited US launch of the devices during the third quarter, with a wider release in early 2026.
0 · Reply
MrTicker
MrTicker Jul. 30 at 2:06 PM
$BVS volume slowly picking up.. about to break through $7+ on news
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 30 at 11:48 AM
$BVS MarketBeat (4 analysts): $13.75 average, ranging from $12.00 to $15.00, implying approximately 110% upside from the $6.53 share price as of July 28, 2025 .
0 · Reply
Latest News on BVS
Bioventus Inc. (BVS) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 12:58 AM EDT - 2 months ago

Bioventus Inc. (BVS) Q2 2025 Earnings Call Transcript


Bioventus Reports Second Quarter Financial Results

Aug 6, 2025, 7:00 AM EDT - 2 months ago

Bioventus Reports Second Quarter Financial Results


Bioventus Inc. (BVS) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:55 PM EDT - 5 months ago

Bioventus Inc. (BVS) Q1 2025 Earnings Call Transcript


Bioventus Reports First Quarter Financial Results

May 6, 2025, 7:30 AM EDT - 5 months ago

Bioventus Reports First Quarter Financial Results


Bioventus Inc. (BVS) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 2:31 PM EDT - 7 months ago

Bioventus Inc. (BVS) Q4 2024 Earnings Call Transcript


Bioventus Inc. (BVS) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 12:26 PM EST - 11 months ago

Bioventus Inc. (BVS) Q3 2024 Earnings Call Transcript


Bioventus Reports Third Quarter Financial Results

Nov 5, 2024, 7:30 AM EST - 11 months ago

Bioventus Reports Third Quarter Financial Results


Executives Buying W. P. Carey And 2 Other Stocks

Aug 21, 2024, 7:37 AM EDT - 1 year ago

Executives Buying W. P. Carey And 2 Other Stocks

WPC GWRS


Bioventus Inc. (BVS) Q2 2024 Earnings Call Transcript

Aug 11, 2024, 1:45 PM EDT - 1 year ago

Bioventus Inc. (BVS) Q2 2024 Earnings Call Transcript


Bioventus, Inc. (BVS) Q1 2024 Earnings Call Transcript

May 7, 2024, 12:02 PM EDT - 1 year ago

Bioventus, Inc. (BVS) Q1 2024 Earnings Call Transcript


Bioventus Inc. (BVS) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 11:00 AM EDT - 1 year ago

Bioventus Inc. (BVS) Q4 2023 Earnings Call Transcript


Bioventus: Bullish On Path To Profitability

Jan 24, 2024, 2:00 PM EST - 1 year ago

Bioventus: Bullish On Path To Profitability


Bioventus Inc. (BVS) Q3 2023 Earnings Call Transcript

Nov 12, 2023, 12:55 AM EST - 2 years ago

Bioventus Inc. (BVS) Q3 2023 Earnings Call Transcript


Bioventus Stock: Improving Outlook Keeps It Interesting

Oct 11, 2023, 5:44 PM EDT - 2 years ago

Bioventus Stock: Improving Outlook Keeps It Interesting


Bioventus to Present at the Cantor Global Healthcare Conference

Sep 19, 2023, 9:52 PM EDT - 2 years ago

Bioventus to Present at the Cantor Global Healthcare Conference


Bioventus Inc. (BVS) Q2 2023 Earnings Call Transcript

Aug 12, 2023, 1:56 PM EDT - 2 years ago

Bioventus Inc. (BVS) Q2 2023 Earnings Call Transcript


Bioventus: Return Of The King

Jun 28, 2023, 2:18 PM EDT - 2 years ago

Bioventus: Return Of The King


Bioventus Completes Divestiture of its Wound Business

May 23, 2023, 7:30 AM EDT - 2 years ago

Bioventus Completes Divestiture of its Wound Business


Bioventus Inc. (BVS) Q1 2023 Earnings Call Transcript

May 16, 2023, 10:53 PM EDT - 2 years ago

Bioventus Inc. (BVS) Q1 2023 Earnings Call Transcript


highnihilism
highnihilism Sep. 22 at 12:52 PM
IWM: Russell 2000 → $CIA Citizens $ACRS Aclaris Therapeutics $PWP Perella Weinberg Partners $APOG Apogee Enterprises $BVS Bioventus
0 · Reply
highnihilism
highnihilism Sep. 17 at 9:40 AM
IWM: Russell 2000 → $CIA Citizens $ACRS Aclaris Therapeutics $PWP Perella Weinberg Partners $APOG Apogee Enterprises $BVS Bioventus Class A
0 · Reply
theDIOyears
theDIOyears Sep. 17 at 4:26 AM
$BVS looking to get in. Anyone able to give me a quick rundown?
0 · Reply
B2iDigital
B2iDigital Sep. 8 at 9:20 PM
Xtant Medical Holdings (NYSE-American: $XTNT) announced that Sean Browne, CEO, and Scott Neils, CFO, will participate in the H.C. Wainwright 27th Annual Global Investment Conference. Xtant Medical is a B2i Digital Featured Company. View the comprehensive profile at https://b2idigital.com/xtant-medical-1. H.C. Wainwright’s 27th Annual Global Investment Conference takes place in New York and virtually, September 8-10, 2025. The company presentation will be available on demand as of Friday, September 5 at 7:00 A.M. (ET). Xtant’s management team will be available for virtual one-on-one meetings on September 8th. Interested investors should contact their representative at H.C. Wainwright & Co., LLC. To register for the event and view the company’s presentation, visit: https://journey.ct.events/view/099ddf07-0cfd-43e7-b98f-ca41f0bc9d7f See the news release at: https://investor.xtantmedical.com/news-releases/news-release-details/xtant-medical-participate-hc-wainwright-27th-annual-global Xtant Medical is led by Chief Executive Officer Sean Browne, Chief Financial Officer Scott Neils, and Chief Operating Officer Mark Schallenberger, who bring extensive expertise in medical device commercialization, corporate finance, and orthobiologic innovation. For more information, visit https://www.xtantmedical.com. Investor inquiries: Kevin Gardner at LifeSci Advisors, [email protected]. Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted XTNT stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of XTNT or any security, and it is not intended to offer any opinion on XTNT as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. $OFIX $BVS
1 · Reply
Eagley3k
Eagley3k Aug. 26 at 7:57 PM
0 · Reply
Eagley3k
Eagley3k Aug. 26 at 7:51 PM
$BVS big battle at 200 WMA support level @$7.10. lets see what happens. in for a pop.
0 · Reply
VectorVanguard
VectorVanguard Aug. 23 at 8:10 AM
$BVS Bioventus Inc is a medical device company facing product challenges and restructuring
0 · Reply
MrTicker
MrTicker Jul. 30 at 2:33 PM
$BVS 10:31 AM EDT, 07/30/2025 (MT Newswires) -- Bioventus(BVS) said Wednesday that the US Food and Drug Administration has given 510(k) clearances for TalisMann and StimTrial, the company's peripheral nerve stimulation, or PNS, devices for chronic pain management. TalisMann targets deeper, larger nerves and is designed to provide long-term relief from chronic nerve pain. StimTrial allows doctors to test how patients respond to PNS therapy before starting full treatment, the company said. The company added that it expects to begin a limited US launch of the devices during the third quarter, with a wider release in early 2026.
0 · Reply
MrTicker
MrTicker Jul. 30 at 2:06 PM
$BVS volume slowly picking up.. about to break through $7+ on news
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 30 at 11:48 AM
$BVS MarketBeat (4 analysts): $13.75 average, ranging from $12.00 to $15.00, implying approximately 110% upside from the $6.53 share price as of July 28, 2025 .
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 30 at 11:47 AM
$BVS The peripheral nerve stimulation market is growing over 20% annually and is projected to exceed $500 million by 2029
0 · Reply
MrTicker
MrTicker Jul. 30 at 11:46 AM
$BVS excellent news...word not out yet
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 30 at 11:45 AM
$BVS Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products By Bioventus, Inc. | July 30, 2025, 7:30 AM
0 · Reply
StockRedBaron
StockRedBaron Jul. 30 at 11:42 AM
$BVS WOW! So HUGE for us!...WHY all the Insider Buying in June!! https://finance.yahoo.com/news/bioventus-receives-fda-510-k-113000698.html
0 · Reply
MrTicker
MrTicker Jul. 30 at 11:39 AM
$BVS These two clearances mark an important step forward for Bioventus(BVS) and represent a substantial growth opportunity as the Company looks to expand in the PNS market, which is currently estimated to be growing above 20 percent annually and expected to exceed $500 million by 2029. With TalisMann™ and StimTrial™ now FDA-cleared, Bioventus(BVS) offers a comprehensive PNS portfolio that empowers physicians to potentially treat a broader spectrum of patients—from initial assessment to long-term therapy—with greater confidence and flexibility. This development also reinforces the Company's commitment to delivering non-opioid, minimally invasive therapies designed to address real-world clinical needs.
0 · Reply
MrTicker
MrTicker Jul. 30 at 11:33 AM
$BVS Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products GLOBENEWSWIRE 6:30 AM ET 7/30/2025
0 · Reply
swingingtech
swingingtech Jun. 20 at 12:08 PM
$FHLC $BVS $BCRX $AVBP https://wallstreetwaves.com/peek-under-the-hood-fhlc-has-21-upside/
0 · Reply
TheLearnerEarner
TheLearnerEarner May. 30 at 2:11 PM
$BVS ✅ Healthcare - Mid Cap - F-Score: 6/9 Analysts: 2x buy rating 👨‍🔬 Intrinsic Value Potential: Excellent 💎 RSI: 39.23 (oversold bullish) 📊🐂 Highest Analysts Price Target: $15.00 (130% above Price) 🌟 Range (12m) $5.28 - $14.38 💰 Positive Free Cash Flow: Yes 🏧 NEWSDESK (last recent article) 📰 https://www.stocktitan.net/news/BVS/bioventus-reports-first-quarter-financial-uudx27wc3fec.html
0 · Reply
11thestate
11thestate May. 16 at 12:17 PM
$BVS agreed to a $15.25M settlement with investors over claims it misled them about unexpected refund claims and financial reporting issues. Who’s eligible? Anyone who bought and held $BVS stock between February 11, 2021 and November 21, 2022. Do I need to sell to qualify? No — you're eligible if you bought during that period, even if you still hold the shares. How much is the payout? Estimated at $0.49 per share — but if only 25% of eligible investors file, it could go up to $1.96 per share. Can I still file? Yes — late claims are currently being accepted. When do payouts happen? Usually 8–12 months after the court grants final approval. To file your claim: https://11th.com/cases/bioventus-investor-lawsuit
0 · Reply
11thestate
11thestate May. 16 at 11:52 AM
$BVS agreed to a $15.25M settlement with investors over claims it misled them about unexpected refund claims and financial reporting issues. Who’s eligible? Anyone who bought and held $BVS stock between November 21, 2022 and December 2, 2024. Do I need to sell to qualify? No — you're eligible if you bought during that period, even if you still hold the shares. How much is the payout? Estimated at $0.49 per share — but if only 25% of eligible investors file, it could go up to $1.96 per share. Can I still file? Yes — late claims are currently being accepted. When do payouts happen? Usually 8–12 months after the court grants final approval. To file your claim: https://11th.com/cases/bioventus-investor-lawsuit
0 · Reply
11thestate
11thestate May. 9 at 12:14 PM
$BVS agreed to a $15.25M settlement with investors over claims it hid unexpected refund demands and financial issues tied to lower average selling prices. Who’s eligible? Anyone who bought and held $BVS stock between February 11, 2021 and November 21, 2022. Do I need to sell my shares to qualify? No — you're eligible if you purchased during that period, regardless of whether you sold or still hold. How much is the payout? Estimated at $0.49 per share, depending on how many investors file. Can I still file? Yes — late claims are currently being accepted, subject to court approval. When do payouts happen? Usually 8–12 months after final approval. To file your claim: https://11th.com/cases/bioventus-investor-lawsuit
0 · Reply
PenkeTrading
PenkeTrading May. 7 at 11:54 AM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of Bioventus Inc. Is that bullish or bearish? $BVS #Bioventus #RsiOversold #NASDAQ
0 · Reply